The Global Factor IX Lyophilized Concentrate Market was valued at USD 938 million in 2023 and is projected to reach USD 2,601.15 million by 2032, growing at a Compound Annual Growth Rate (CAGR) of 12.00% during the forecast period (2025–2032). This expansion is driven by increasing hemophilia B prevalence, rising demand for efficient clotting therapies, and technological advancements in lyophilization processes that enhance product stability and shelf life.
As the hemophilia treatment sector evolves with novel therapeutic approaches, leading biopharmaceutical companies are expanding their Factor IX portfolios through significant R&D investments and strategic collaborations. This analysis examines the Top 10 Companies in the Factor IX Lyophilized Concentrate Market – global leaders and innovative specialists transforming hemophilia B care worldwide.
🔟 1. CSL Behring
Headquarters: King of Prussia, Pennsylvania, USA
Key Products: Mononine®, Idelvion®
CSL Behring dominates the hemophilia treatment landscape with a comprehensive portfolio featuring both plasma-derived and recombinant Factor IX concentrates. Their Mononine® (human coagulation Factor IX) remains a gold standard lyophilized treatment for hemophilia B patients globally.
Strategic Advantages:
- Industry-leading recombinant Factor IX therapies with extended half-life
- Active clinical pipeline for next-generation hemophilia treatments
- Global manufacturing and distribution network ensuring stable supply
Download FREE Sample Report: Factor IX Lyophilized Concentrate Market – View in Detailed Research Report
9️⃣ 2. Grifols
Headquarters: Barcelona, Spain
Key Product: AlphaNine® SD
Grifols maintains a strong position in plasma-derived therapies, with AlphaNine® SD serving as its flagship Factor IX concentrate. The company operates one of the world’s most extensive plasma collection networks, ensuring robust product supply.
Strategic Advantages:
- 3.5 million liters of annual plasma collection capacity
- Advanced viral inactivation methodologies
- Expanding footprint in developing markets
8️⃣ 3. Octapharma
Headquarters: Lachen, Switzerland
Key Product: nonafact®
Octapharma’s nonafact® represents a high-purity human coagulation Factor IX concentrate approved for both hemophilia B treatment and surgical prophylaxis, with established clinical efficacy across patient populations.
Strategic Advantages:
- Continuous purification process improvements
- Strong clinical evidence base for surgical applications
- Extensive European plasma collection infrastructure
7️⃣ 4. Prothya Biosolutions
Headquarters: Amsterdam, Netherlands
Key Product: Factor IX (Haemonine®)
Formerly operating as Sanquin Plasma Products, Prothya Biosolutions delivers high-quality plasma-derived Factor IX concentrates with multi-pathogen safety measures, serving critical European markets.
Strategic Advantages:
- Proprietary chromatography purification technologies
- Active participation in European patient registries
- Cutting-edge viral clearance methodologies
Download FREE Sample Report: Factor IX Lyophilized Concentrate Market – View in Detailed Research Report
6️⃣ 5. Takeda Pharmaceutical Company
Headquarters: Tokyo, Japan
Key Products: BeneFIX®, Immunine®
Through strategic acquisitions, Takeda has strengthened its hemophilia portfolio with BeneFIX®, the pioneering recombinant Factor IX therapy, maintaining strong market presence through extensive clinical experience.
Strategic Advantages:
- World’s most clinically studied Factor IX product
- Emerging gene therapy pipeline for hemophilia B
- Expanding access programs for developing nations
5️⃣ 6. Pfizer
Headquarters: New York, USA
Key Product: BeneFIX® (legacy product)
While transitioning focus toward gene therapies, Pfizer continues supplying BeneFIX® through strategic partnerships, leveraging decades of hemophilia treatment expertise and global distribution networks.
Strategic Advantages:
- Established brand recognition and physician trust
- Maintained manufacturing quality and reliability
- Comprehensive patient support services
4️⃣ 7. Baxalta (Now Part of Takeda)
Headquarters: Zurich, Switzerland
Key Product: Rixubis®
Baxalta’s innovative Rixubis® recombinant Factor IX concentrate has been integrated into Takeda’s hemophilia portfolio, bringing enhanced treatment options to the global market.
Legacy Contributions:
- Breakthrough recombinant technology development
- Extensive clinical trial database
- Patient-focused administration systems
3️⃣ 8. Bio Products Laboratory (BPL)
Headquarters: Hertfordshire, UK
Key Product: Factor IX Concentrate
BPL manufactures high-purity plasma-derived Factor IX concentrates serving the UK National Health Service and international markets through its advanced fractionation facilities.
Strategic Advantages:
- £200 million facility modernization program
- Expanded international regulatory approvals
- Enhanced donor screening protocols
2️⃣ 9. LFB Biomedicaments
Headquarters: Les Ulis, France
Key Product: Factane®
LFB holds a leading position in France’s plasma protein therapeutics market, with Factane® serving as its standard-bearer in Factor IX replacement therapies for hemophilia B patients.
Strategic Advantages:
- France’s largest plasma collection network
- Innovative combination clotting factor development
- Active in European research consortia
1️⃣ 10. Green Cross Corporation
Headquarters: Yongin, South Korea
Key Product: Green Nine®
As Asia’s foremost Factor IX concentrate manufacturer, Green Cross Corporation provides critical treatment options across the region through its plasma fractionation expertise.
Strategic Advantages:
- 38 plasma collection centers across Asia
- Latest generation viral safety technologies
- Regional healthcare partnerships expanding access
Get Full Report Here: Factor IX Lyophilized Concentrate Market – View in Detailed Research Report
🧬 Market Outlook: The Evolving Landscape of Hemophilia B Treatment
The Factor IX concentrate market is undergoing transformation as novel therapies emerge, though lyophilized products maintain critical importance due to their reliability, established safety, and cost-effectiveness in global healthcare systems.
📈 Key Market Shaping Trends:
- Accelerating transition to recombinant products in developed markets
- Growing adoption of extended half-life Factor IX therapies
- Emerging competition from gene therapy alternatives
- Improved diagnosis and treatment access in emerging economies
- Advanced lyophilization technologies enhancing product characteristics
Get Full Report Here: Factor IX Lyophilized Concentrate Market – View in Detailed Research Report
The featured companies represent the innovators and standard-bearers in hemophilia B treatment, continually advancing therapeutic science while ensuring reliable access to life-saving therapies worldwide.